Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Proceeds to fund company's clinical trials, commercial product launch, and working capital
Initial conversion price set at $1.50 per share
所得資金用於公司的臨床試驗、商業產品推出和營運資金
初始轉換價格定為每股1.50美元
SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced today that it has entered into a securities purchase agreement with Lind Global Fund II LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together the "Investor") to issue and sell the initial $3 million tranche of a total anticipated $10 million private placement with $2 million funded at closing and $1 million to be funded subject to shareholder approval, effective registration statement and conditions specified in the agreement.
加利福尼亞州聖迭戈/ACCESSWIRE/2023年9月25日/Ainos,Inc.(納斯達克股票代碼:AIMD,AIMDW)(以下簡稱“公司”)是一家多元化的醫療保健公司,專注於開發人工智慧支持的護理點檢測、低劑量幹擾素療法和合成核糖核酸驅動的預防藥物。該公司今天宣佈,它已與Lind Partners管理的投資基金Lind Global Fund II LP簽訂了一項證券購買協定。一家總部位於紐約的機構基金經理(統稱“投資者”)將發行和出售預計總價值1,000萬美元私募中的首批300萬美元,其中200萬美元將在交易完成時提供資金,100萬美元將在股東批准、有效註冊聲明和協議規定的條件下提供資金。
The investment is in the form of a Senior Secured Convertible Promissory Note (the "Note"). The Note has an 18-month maturity. In addition, the Note will be convertible into Ainos' shares of common stock at an initial conversion price equal to $1.50 per share and subject to adjustment as further specified in the Note. The Note will be repayable in cash upon maturity. Prior to maturity, the Investor can convert to common stock at conditions specified in the agreement, following the earlier of (i) 90 days from closing or (ii) effective registration statement. The Note contains certain prepayment options and participation rights. The private placement is subject to customary closing conditions. As part of the investment, the Investor was also granted five-year warrants equal to 75% of the funded amount at an initial exercise price equal to $0.90 per share of common stock, subject to adjustment.
投資以高級擔保可轉換本票(“票據”)的形式進行。票據的到期日為18個月。此外,票據將可轉換為Ainos的普通股,初始轉換價格相當於每股1.50美元,並可根據票據的進一步規定進行調整。票據將於到期時以現金償還。在到期之前,投資者可以在協定規定的條件下轉換為普通股,遵循(I)自交易結束起90天或(Ii)有效登記聲明中的較早者。票據包含某些預付款選擇權和參與權。私募受慣例成交條件的約束。作為投資的一部分,投資者還獲得了相當於籌資金額75%的五年期認股權證,初始行權價相當於普通股每股0.90美元,但有可能進行調整。
Maxim Group LLC is acting as the lead placement agent for the private placement. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as the co-placement agent for the private placement.
Maxim Group LLC將擔任此次私募的牽頭配售代理。Arcadia Securities,LLC的子公司Brookline Capital Markets將擔任此次私募的共同配售代理。
Ainos has agreed to file a registration statement registering for the resale of the shares of common stock issuable upon the conversion of the Note and upon the exercise of the warrants. Upon the shareholder approval and effectiveness of the resale registration statement, and subject to the satisfaction of certain conditions, additional tranches of funding may be provided by mutual agreement of the Investor and the Company in the aggregate amount up to $7.0 million. The Investor will be entitled to receive an additional warrant equal to 75% of the increased funding amount with an exercise price equal to 125% of the average of the ten (10) daily VWAPs during the ten (10) trading days prior to the subsequent closing date.
Ainos已同意提交一份登記聲明,登記在轉換票據和行使認股權證時可發行的普通股股份的轉售。於股東批准轉售登記聲明及生效後,並在滿足若干條件下,經投資者及本公司雙方同意,可提供總額最高達700萬美元的額外資金。投資者將有權獲得相當於增資金額75%的額外認股權證,行使價格相當於隨後成交日期前十(10)個交易日十(10)個交易日每日十(10)筆VWAP平均值的125%。
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
本新聞稿不應構成出售這些證券的要約或邀請購買這些證券的要約,也不應在任何州或其他司法管轄區的任何州或其他司法管轄區出售這些證券,在根據任何此類州或其他司法管轄區的證券法進行登記或獲得資格之前,在這些州或其他司法管轄區出售此類證券將是非法的。
Ainos plans to use the proceeds from this financing to fund clinical trials, commercial product launch, and working capital.
Ainos計劃將此次融資所得資金用於臨床試驗、商業產品發佈和營運資金。
About The Lind Partners
關於Lind Partners
The Lind Partners manages institutional funds that are leaders in providing growth capital to small- and mid-cap companies publicly traded in the US, Canada, Australia and the UK. Lind's multi-strategy funds make direct investments ranging from US$1 to US$30 million, invest in syndicated equity placements and selectively buy on market. Having completed more than 200 direct investments totaling over US$2 billion in transaction value, Lind's funds have been flexible and supportive capital partners to investee companies since 2011.
Lind Partners管理的機構基金在向在美國、加拿大、澳大利亞和英國上市的中小型公司提供增長資本方面處於領先地位。Lind的多策略基金直接投資1至3,000萬美元,投資於銀團配股,並有選擇地在市場上買入。自2011年以來,林德的基金已經完成了200多項直接投資,總交易額超過20億美元,一直是靈活和支持被投資公司的資本合作夥伴。
About Ainos, Inc.
關於Ainos公司
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common STIs. To learn more, visit
Ainos總部設在加利福尼亞州聖地亞哥,是一家多元化的醫療保健公司,專注於開發新型的護理點檢測(POCT)、低劑量VELDONA幹擾素療法和合成RNA驅動的預防性藥物。該公司的產品包括VELDONA臨床階段人類療法、VELDONA Pet細胞蛋白健康補充劑,以及由其AI鼻部技術平臺支持的遠端健康友好POCT。主要的POCT候選人Ainos Flora打算成為一個有利於遠端保健的POCT,用於婦女健康和某些常見的性傳播感染。要了解更多資訊,請訪問
Follow Ainos on X, formerly known as Twitter (@AinosInc) and LinkedIn to stay up-to date.
關注X上的Ainos,前身為Twitter(@AinosInc)和LinkedIn,以保持最新。
Forward-Looking Statements
前瞻性陳述
This press release includes "forward-looking statements" within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are made in reliance upon the "safe harbor" protections provided by such acts for forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements describing the Company's objectives, plans or goals are, or may be, forward-looking statements.
本新聞稿包括修訂後的1933年證券法第27A節和修訂後的1934年證券交易法(“交易法”)第21E節中該術語所指的“前瞻性聲明”,這些前瞻性聲明是基於此類法案為前瞻性聲明提供的“安全港”保護而作出的。前瞻性陳述可以通過使用“預期”、“相信”、“估計”、“預期”、“打算”、“計劃”、“預測”、“專案”、“目標”、“未來”、“可能”、“戰略”、“預見”、“可能”、“指導”、“潛在”、“展望”、“預測”、“應該,“Will”或其他類似的單字或短語。同樣,描述公司目標、計劃或目標的陳述是或可能是前瞻性陳述。
Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside the Company's control. The Company's results may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the Company's dependence on revenues from the sale of COVID-19 test kits and its VELDONA Pet product line; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; and the Company's success in managing the growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K, as amended, and its subsequent filings with the SEC. Many of these risks are beyond the Company's control. There may be additional risks that we consider immaterial or that are unknown, and it is not possible to predict or identify all such risks.
前瞻性陳述僅基於公司目前的信念、預期和假設。前瞻性陳述會受到固有的不確定性、風險和難以預測的環境變化的影響,其中許多都不在公司的控制範圍之內。該公司的結果可能與前瞻性陳述中指出的大不相同。可能導致公司的實際結果與本新聞稿中討論的預測、預測、估計和期望大不相同的重要因素包括,公司對新冠肺炎檢測試劑盒和VELDONA銷售收入的依賴寵物產品線;公司有限的現金和虧損歷史;公司實現盈利的能力;公司籌集額外資本以繼續公司的產品開發的能力;準確預測公司未來經營結果的能力;通過臨床試驗推進Ainos當前或未來候選產品的能力,獲得市場批准並最終將公司開發的任何候選產品商業化的能力;獲得並保持對Ainos候選產品的監管批准的能力;延遲完成公司當前和未來候選產品的開發和商業化,這可能會導致公司成本增加,延遲或限制創收能力,並對公司的業務、財務狀況、運營結果和前景產生不利影響;公司行業內激烈的競爭和快速進步的技術可能超過其技術;客戶對公司開發的產品和服務的需求;競爭或替代產品、技術和定價的影響;研發設施的中斷;第三方的訴訟和其他索賠或管理公司運營的各種監管機構的調查;潛在的網路安全攻擊;與網路安全相關的更高要求和成本;公司實現第三方許可協定利益的能力;公司獲得和維護Ainos候選產品知識產權保護的能力;遵守適用的法律、法規和關稅;以及公司成功管理增長。對這些風險因素和其他風險因素的更完整的描述包含在Ainos公司經修訂的Form 10-K年度報告以及隨後提交給美國證券交易委員會的檔案中的“風險因素”一節。其中許多風險都不在公司的控制範圍之內。可能還有我們認為不重要或未知的額外風險,而且不可能預測或識別所有這些風險。
Ainos cautions that the foregoing list of factors is not exclusive. Ainos also cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Ainos警告說,上述因素列表並不是排他性的。Ainos還告誡讀者不要過度依賴任何前瞻性聲明,這些聲明只反映了做出的日期。Ainos不承擔任何義務,也明確不承擔任何此類義務,公開更新或修訂任何前瞻性陳述,以反映假設的變化、預期或意外事件的發生或未來結果的變化,除非法律另有要求。
Investor Relations Contact
投資者關係聯繫人
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com
ICR,LLC
楊彥宏
電話:+1646-224-6971
電子郵件:Ainos.IR@icrinc.com
SOURCE: Ainos, Inc.
資料來源:Ainos公司